Eisai
Eisai Co., Ltd., commonly referred to as Eisai, is a prominent global pharmaceutical company headquartered in Japan. Established in 1941, Eisai has made significant strides in the healthcare industry, focusing on the discovery, development, and marketing of innovative medicines. With major operational regions across Asia, Europe, and North America, the company is dedicated to addressing unmet medical needs, particularly in neurology and oncology. Eisai's core products include treatments for Alzheimer's disease and various cancers, distinguished by their commitment to patient-centric solutions. The company has achieved notable recognition for its research and development efforts, positioning itself as a leader in the pharmaceutical sector. With a strong emphasis on ethical practices and collaboration, Eisai continues to enhance its market presence while striving to improve the quality of life for patients worldwide.
DitchCarbon Score
How does Eisai's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eisai's score of 54 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Eisai's reported carbon emissions
In 2023, Eisai Co., Ltd., headquartered in Japan, reported total greenhouse gas emissions of approximately 48586000 kg CO2e for Scope 1, 2673000 kg CO2e for Scope 2, and a significant 563928000 kg CO2e for Scope 3 emissions. This reflects a slight increase in Scope 1 emissions from 47507000 kg CO2e in 2022, while Scope 2 emissions decreased from 6105000 kg CO2e. Scope 3 emissions also saw a reduction from 602655000 kg CO2e in the previous year. Eisai has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 55% by fiscal 2030 from a 2019 base year. Additionally, the company targets a 27.5% reduction in Scope 3 emissions (specifically from purchased goods and services) within the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and are classified under the 1.5°C pathway, indicating a commitment to significant climate action. Furthermore, Eisai has pledged to achieve net-zero emissions across all scopes by 2050, reinforcing its long-term sustainability goals. The company’s emissions data and reduction targets are sourced directly from Eisai Co., Ltd., with no cascading from a parent organization.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 49,457,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 55,830,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 456,386,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eisai is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
